Proteogenomics Reveals how Metastatic Melanoma Modulates the Immune System to Allow Immune Evasion

Jeovanis Gil^{1,16,*}, Yonghyo Kim^{1,16}, Beáta Szeitz^{2,16}, Viktória Doma^{3,4}, Uğur Çakır³, Natália Pinto de Almeida^{5,6}, Yanick Paco Hagemeyer^{7,8}, Victor Guryev⁷, Jenny G Johansson⁹, Yogita Sharma⁹, Indira Pla Parada¹⁰, Zsolt Horvath⁵, Jéssica de Siqueira Guedes⁶, Gustavo Monnerat⁶, Gabriel Reis Alves Carneiro⁶, Fábio CS Nogueira⁶, Boram Lee¹, Henriett Oskolas¹, Enikő Kuroli³, Judit Hársing³, Yutaka Sugihara¹, Magdalena Kuras¹⁰, Roger Appelqvist¹, Elisabet Wieslander¹, Gilberto B Domont⁶, Bo Baldetorp¹, Runyu Hong¹¹, Gergely Huszty¹², Laura Vizkeleti⁴, József Tímár⁴, David Fenyő¹¹, Lazaro Hiram Betancourt¹, Johan Jakobsson⁹, Johan Malm¹⁰, Aniel Sanchez¹⁰, A. Marcell Szász^{2,13}, Peter Horvátovich⁸, Melinda Rezeli⁵, Sarolta Kárpáti^{3,17}, and György Marko-Varga^{5,14,15,17}

- 1- Division of Oncology, Department of Clinical Sciences Lund, Lund University, **Lund, Sweden**
- 2- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, **Budapest, Hungary**
- 3- Dermatology, Venereology and Dermatooncology, Semmelweis University, **Budapest, Hungary**
- 4- Second Department of Pathology, Semmelweis University, **Budapest, Hungary**
- 5- Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, **Lund, Sweden**
- 6- Chemistry Institute, Federal University of Rio de Janeiro, **Rio de Janeiro, Brazil**
- 7- European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, **Groningen, The Netherlands**
- 8- Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, **Groningen, The Netherlands**
- 9- Laboratory of Molecular Neurogenetics, Department of Experimental Medical Science, Lund University, **Lund, Sweden**
- 10- Section for Clinical Chemistry, Department of Translational Medicine, Lund University, **Malmö, Sweden**
- 11- Institute for Systems Genetics and Department of Biochemistry and Pharmacology, New York University, Grossman School of Medicine, **New York, USA**
- 12- Department of Transplantation and Surgery, Semmelweis University, **Budapest, Hungary**
- 13- Department of Bioinformatics, Semmelweis University, **Budapest, Hungary**
- 14- Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, **Seoul, Republic of Korea**
- 15- 1st Department of Surgery, Tokyo Medical University, **Tokyo, Japan**
- 16- These authors contributed equally
- 17- Senior author

* correspondence: jeovanis.gil_valdes@med.lu.se (Jeovanis Gil)

TOC figure:

Summary:

Malignant melanoma (MM) develops from the melanocytes and in its advanced stage is the most aggressive type of skin cancer. Here we report a comprehensive analysis on a prospective cohort study, including non-tumor, primary and metastasis tissues (n=77) with the corresponding plasma samples (n=56) from patients with malignant melanoma. The tumors and surrounding tissues were characterized with a combination of high-throughput analyses including quantitative proteomics, phosphoproteomics, acetylomics, and whole exome sequencing (WES) combined with in-depth histopathology analysis. Melanoma cell proliferation highly correlates with dysregulation at the proteome, at the posttranslational- and at the transcriptome level. Some of the changes were also verified in the plasma proteome. The metabolic reprogramming in melanoma includes upregulation of the glycolysis and the oxidative phosphorylation, and an increase in glutamine consumption, while downregulated proteins involved in the degradation of amino acids, fatty acids, and the extracellular matrix (ECM) receptor interaction. The pathways most dysregulated in MM including the MAP kinases-, the PI3K-AKT signaling, and the calcium homeostasis, are among the most affected by mutations, thus, dysregulation in these pathways can be manifested as drivers in melanoma development and progression.

The phosphoproteome analysis combined with target-based prediction mapped 75% of the human kinome. Melanoma cell proliferation was driven by two key factors: i) metabolic reprogramming leading to upregulation of the glycolysis and oxidative phosphorylation, supported by HIF-1 signaling pathway and mitochondrial translation; and ii) a dysregulation of the immune system response, which was mirrored by immune system processes in the plasma proteome. Regulation of the melanoma acetylome and expression of deacetylase enzymes discriminated between groups based on tissue origin and proliferation, indicating a way to guide the successful use of HDAC inhibitors in melanoma. The disease progression toward metastasis is driven by the downregulation of the immune system response, including MHC class I and II, which allows tumors to evade immune surveillance. Altogether, new evidence is provided at different molecular levels to allow improved understanding of the melanoma progression, ultimately contributing to better treatment strategies.

Keywords:

melanoma, proteogenomics, phosphoproteomics, lysine acetylation, evasion of immune surveillance, metabolic reprogramming, MHC class I, MHC class II, tumor proliferation

1. Introduction

Among the skin cancers, malignant melanoma is the deadliest, and its incidence and mortality are rising, particularly in Europe^{1,2}. However, the early surgical intervention, and more recently the advent of targeted therapy and immunotherapy have substantially improved the mortality rate of the disease. Melanoma is one of the most heterogeneous cancers at the genomic level, which results in a variety of distinct phenotypes of the disease³. The high level of heterogeneity in melanoma has been previously linked to disease progression and short survival^{4,5}. Additionally, the levels of mutated proteins and dysregulation of their biological pathways, critically impact the tumor biology and survival⁶. Signaling pathways such as the PI3K-AKT, mTOR, and MAPK are usually dysregulated in melanoma. BRAF, which is a kinase involved in the MAPK/ERK signaling pathway is the most frequently observed driver mutation in melanoma counting for approximately 50% of cases⁷. Thus, a common treatment strategy to target this pathway is to use a combination of BRAF and MEK inhibitors. After a progression free period, however, most of the responsive patients in stage 4 of the disease develop resistance to treatment and ultimately die.

Large cohorts of melanoma samples have been studied through genomics, transcriptomics, proteomics in attempts to decipher the molecular mechanisms driving the development and progression of the disease^{8,9}. Phosphoproteomics and acetylomics on melanoma have shown dysregulation during the progression of the disease at the posttranslational level^{10,11}. Additionally, a recent international milestone was reported; the high-stringency blueprint of the human proteome¹², mapping the expression and functional annotation of the coded genome. In an attempt to integrate several high-throughput analyses into the biological understanding of the development and progression of melanoma, we performed a comprehensive multi-omic analysis including proteomics, PTM profiling, metabolomics, and whole-exome sequencing of 77 tissue samples coming from 47 melanoma patients, supplemented by the proteomic analysis of 56 plasma samples. The metabolic changes that take place during the development and progression of the disease were traced at different molecular levels. We demonstrated that the characterization of melanoma in such an integrative manner at different molecular levels led to a better biological understanding of the disease that will ultimately help to advance future therapeutic interventions

2. Results

2.1. Characteristics of the melanoma-related prospective cohort study

A cohort of 77 solid tissues, and 56 blood samples, originating from 47 different melanoma patients, enrolled in a prospective study, were submitted to a multi-omic analysis. Fresh frozen

biopsies originated from different organs and body localizations, including non-tumors (NT; >2 cm from the tumor edges; n=11), tumor microenvironments (TM; tumor edge without countable tumor cells; n=6), primary tumors (PT; n=16), local recurrences (LR; n=6), cutaneous metastases (CM; n=10), regional lymph node metastases (LN; n=23), and distant metastases (DM; coming from gallbladder, brain, liver, spleen, and breast; n=5) (Figure 1A). Blood sampling was performed prior to the surgical isolation of the tumor tissues. The relevant clinical information of the patients included in the study is presented in Table S1. All

samples were submitted to quantitative proteomics. Besides, the tissue samples were subjected to quantitative phosphoproteomics and lysine acetylation stoichiometry analysis (Figure 1B). Complementary whole-exome sequencing (WES) was performed on the tumor tissue samples (60). The disease presentation within the tumors from the patients is outlined in Figure 1C, where grading was made according to the immune competence, as well as the tumor burden encompassing the metastasis types, the primary and non-tumors.

Figure 1. Melanoma-related cohort submitted to multi-omics approach. **A)** Tissue samples originated from non-tumor (green, n=11), tumor microenvironment (purple, n=6), primary tumor (n=16), local recurrence (orange, n=6), cutaneous metastasis (n=10), lymph node metastases (n=23), and distant metastasis (n=5). **B)** Workflow for the global proteomics, phosphoproteomics, and acetylomics used in tissue-derived samples. Tissue samples were sectioned (10 μ m thickness), sonicated using Bioruptor plus in SDS containing buffer. The proteins were acetylated with N-

acetoxysuccinimide-d3 (NAS-d3), followed by trypsin digestion. Generated peptides were divided into three different analyses; one fraction was directly injected onto LC-MS/MS system and analyzed following a data-independent analysis (DIA) method. A second fraction was submitted to an automated phosphopeptide enrichment analysis before LC-MS/MS analysis in a classical DDA method. The third fraction was measured following a DDA method without additional processing. Global proteomics data were analyzed with Spectronaut software, phosphoproteomics data was processed with Proteome Discoverer and acetylomics data by the combination of Proteome Discoverer and Pview. **C)** Spectrum of tumor-immune system imbalance is depicted during the progression of the disease. Starting from a relatively competent immunologic state both in peritumoral and intratumoral regions of low tumor load the pathological process ultimately results in high tumor burden with an exhausted immune system. Greyscale images correspond to the color figures above displaying areas of tumor (T), lymphoid infiltrate (L), and stroma (S). Oftentimes, this latter microenvironment adjacent to actual tumor cell nests is also dark (macroscopically), contains macrophages performing melanin phagocytosis.

2.2. Dysregulated pathways in melanoma carry a large mutation load

The tumor tissue samples were submitted to whole-exome sequencing (WES) analysis. In the absence of normal tissues as control, we relied on the gnomAD database's non The Cancer Genome Atlas (TCGA) subset of ExAC release 1 to estimate the "population background". The analysis revealed that melanoma does carry a higher number of somatic mutations, as compared to germline mutations (A>T and T>A SNP mutations, and indels are 15 and 224 times more abundant). However, the variants corresponding to SNP changes; A>G and T>C, were found to be underrepresented, whereas C>T and G>A were at comparable levels in somatic compared to germline mutations (**Table S2**). The relative ratio of different equivalent base-pair changes in somatic and germline SNPs variants are consistent across samples and the somatic patterns are different from the germline one. Germline patterns show high similarity with the population background except for A>G and T>C mutations, which is considerably larger in the germline pattern of the analyzed tumors compared to the population background (**Figure S1A-B**). The ratio of indels and SNPs in somatic mutations is substantially lower than in germline variants (0.81 ± 0.03 and 74.53 ± 4.48 SNPs/indels ratio respectively), indicating that melanoma is driven by indels rather than SNPs (**Figure 2D**). Differences in this ratio were not observable, based on the sample origin. We also found that indels are slightly extending exon and protein sequences in somatic variants, while germline indels tend to mainly shorten them (**Figure S2**). The highly reproducible somatic patterns suggest that mutations in melanoma are driven by similar underlying molecular mechanisms across all patients.

The high genetic heterogeneity of melanoma tumors was highlighted by lower sequence coverage of somatic compared to germline variants. While germline mutations are expected to be present in all cells, somatic mutations are only present in tumor cells, and different clones carry different somatic mutations (**Figure S3**). We performed hot spot analysis to identify the genes most frequently found carrying somatic mutations across the samples using a Chi-squared test followed by a multiple testing with Bonferroni correction. We were able to locate the chromosomal regions with somatic mutation burden (**Figure S4**). Genes that were significantly mutated in at least one-third of the samples (20 out of 60) were selected as hot spots (132 genes in total) (**Figure 2A, Table S3**). The functional annotation analysis revealed that to a large extent, these genes are involved in the interaction and regulation of the immune system (**Figure 2B**). Particularly, the genes coding for the protein elements of both MHC complexes class I and II carry mutations in most melanoma samples. To a lesser extent, genes functionally related to metabolism and signaling cascades were also among the most mutated genes.

The most dysregulated pathways in melanoma found in this study at the transcriptional, translational, and posttranslational level, were also found to carry a significantly higher level of both germline and somatic mutations than the background population (**Figure 2C, Table S4**). In this sense, the pathways most affected by mutations in melanoma are the signaling cascades including MAP kinases and PI3K-AKT, and the calcium homeostasis. Not surprisingly, dysregulations of these pathways have been considered drivers in melanoma development and progression. On average, these pathways carry at least 11 times more somatic than germline mutations, which indicates that the genes of these pathways are heavily affected by the mutation burden in melanoma.

Figure 2. Most mutated genes in melanoma are involved in the regulation of the immune system. A) List of genes identified as hot spots in at least one-third (20 samples out of 60) of the tumor cohort. **B)** Protein-protein interaction network of the hot spot genes. Highlighted in red are the protein elements of the complexes MHC class I and II, and in blue additional proteins involved in processes related to the regulation of the immune system. **C)** Violin plots showing the number of somatic (left axis) and germline (right axis) mutations in genes involved in 16 KEGG pathways known to play crucial roles and found dysregulated in melanoma. The numbers inside the graph represent the number of mutations in the pathway and the

percentage indicates the total number of genes detected in WES data relative to the total number of genes in the pathway. Data with the summary of the figure are outlined in **Table S4. D**) Number of mutations (indels vs. SNPs) for somatic and germline mutations in each sample on a logarithmic scale. Zoomed-in regions for somatic and germline mutations are shown.

2.3. Proteome profiling of biopsies from melanoma patients

Tissue samples were submitted to a workflow that allows, from the same sample processing, to perform quantitative proteomic, phosphoproteomic, and lysine acetylation stoichiometry analysis^{10,13} (**Figure 1B**). Briefly, the frozen tissue was sliced, and 15 consecutive slices were used for proteomics and PTMs analysis, or whole-exome sequencing. The first and last slices were H&E stained for computing the sample composition (tumor, stroma, and immune cell content). Proteins extracted, followed by chemically acetylated with NAS-d3 and digested with trypsin. Generated peptides were delimited by arginine residues. For global proteomics, peptides were directly analyzed by high-resolution mass spectrometry following a data-independent analysis (DIA) method. The phosphoproteome analysis included an automated phosphopeptide enrichment step using IMAC (Fe(III)-NTA), followed by high-resolution mass spectrometry data-dependent analysis (DDA). For lysine acetylation stoichiometry analysis, peptides were analyzed following a DDA method for acquisition (**Figure 1B**).

The proteomic analysis resulted in the identification and quantification of 9040 proteins with more than 2500 identified in all analyzed samples (**Figure 3**). On average, we identified approximately 7000 proteins in the tumor samples. 17237

phosphorylated peptides were identified in phosphoproteomics data, approximately 8000 in each sample. Additionally, we identified and determined the site-specific occupancy of 6844 acetylated peptides in at least 3 different samples, which correspond to 3024 different proteins. The plasma proteome analysis of the patients resulted in the identification of 1370 proteins.

From the proteomic data, the relative abundance profiles of the protein elements of the minichromosome maintenance (MCM) complex were extracted and submitted to hierarchical clustering analysis. As a resulting outcome, all samples were grouped into four groups from lower to higher levels of the complex elements (**Figure 3**). MCM is a hetero-hexameric complex required for DNA replication, which possesses DNA helicase activity¹⁴⁻¹⁷. Due to its role in DNA replication and because their protein elements have been reported as proliferation markers and associated with progression in many cancers^{14,15,25,26,16,18-24}, we procured their protein abundance profiles as a measure of the proliferation-rate of the sample. The levels of the well-known proliferation marker Ki-67 showed significant differences between the proliferation groups, where the groups with higher MCM complex levels, also upregulate Ki-67 (**Figure 3**). As expected, non-tumor and tumor microenvironment samples were grouped in the low proliferative groups and Ki-67 was not detectable in any of them.

Figure 3. Proteomics of fresh frozen tissue biopsies from melanoma patients. A total of 77 samples coming from 47 different patients are grouped according to their origin. Eleven Non-tumor (NT) biopsies from more than 2 cm from the tumor boundaries, six tumor microenvironment (TM) samples taken from the tumor edges without the presence of tumor cells, sixteen biopsies from primary tumors (PT), six biopsies from local recurrence (LR) of the disease, ten biopsies of cutaneous metastases (CM), twenty-three metastases in regional lymph nodes, and five distant metastases (DM) coming from the gallbladder (DM036), brain (DM078), liver (DM087), spleen (DM107) and breast (DM116). Bars indicate the number of proteins quantified in each sample. The cell composition of each sample, taking into account tumor cell, stroma, and immune cells was estimated and expressed in percentage of the total sample area. The heatmap was built with the relative abundance levels shown as Z-scores of the six protein elements of the mini-chromosome maintenance complex and four clusters were created to represent the proliferation status of the samples. The abundance of the proliferation marker Ki-67 was plotted for each sample in the proliferation groups. A line indicates the mean value for each group relative to the most proliferative sample group. The colored connection arcs link the samples' origin with their proliferation status.

2.4. Melanoma proliferation relies on repressing the immune system response-related pathways

We sought to gain a deeper understanding of what processes are altered with increased tumor cell proliferation. This was addressed using the proteomic data of the 60 tumor tissue samples and 56 paired plasma samples as well as the Skin Cutaneous Melanoma TCGA PanCancer data with 443 tumor tissue samples (involving 20531 transcripts). TCGA tissue samples were classified into proliferation groups based on the MCM complex levels (in the same manner as the proteomic dataset), whereas the plasma samples were annotated according to the corresponding tissue sample. Sparse partial least squares discriminant analysis (sPLS-DA, ²⁷) of these plasma samples showed there is good discrimination between the high and low proliferation groups, indicating that tumor proliferation status is reflected in the plasma proteome (**Figure 4D**).

Differential expression analysis resulted in 598 proteins (**Figure 4A**) and 1523 transcripts (**Figure 4B**) with significant differential expression across the proliferation groups (ANOVA test FDR < 0.001). The overlap between these significant components was rather sparse on the gene level (**Figure 4C**), however, this list of proteins and genes both suggest an upregulation of cell cycle processes. Also, similar upregulation of proteins that were involved in the organization and localization of cellular components, and an increased biosynthesis of nucleotides. The latter process is particularly important for proliferation because nucleotides cannot be directly taken up from the extracellular space in larger quantities ²⁸. We additionally performed pre-ranked Gene Set Enrichment Analysis (GSEA) to see which MSigDB hallmark gene sets are concordantly up-, or down-regulated in highly proliferating tumors. The majority of these processes received similar enrichment scores, in both omics data (**Figure 4E**), strengthening the idea, that RNA-level data from TCGA is a valuable resource for supplementing our protein-level results. We observed a systematic downregulation of immune-related processes, which is associated with increased proliferation, possibly due to a lack of immunoediting at a more progressed stage of the disease ²⁹. The relation between immune

system modulation and tumorigenesis in melanoma has been studied for the past few years, where today immunotherapies are the most effective treatment options for melanoma patients ³⁰. Our observation provides evidence, supported by the high mutational load, that melanoma development and proliferation rely on evasion of the immune surveillance by downregulating immune response-related pathways.

Plasma proteins with altered abundance profiles across proliferation groups were delineated by selecting the top 100 proteins that drive the discrimination of groups according to the sPLS-DA analysis. These proteins are related to the: immune system, extracellular structure organization, vesicle-mediated transport, platelet degranulation and activation, acute-phase, cell migration, and apoptosis (**Figure 4F**). It has been shown that the platelets play a central role in the tumor growth and metastasis development in, melanoma, along with additional other cancer diseases. There is evidence postulating that tumor cells interact with platelets, thereby inducing aggregation as well as degranulation ^{31–34}. Regarding the extracellular structure organization, it has been shown that extracellular matrix proteins have a role in the cell transformation process since they are responsible for the interaction between cells and the microenvironment ³⁵. Moreover, inflammatory process and cancer development are inter-connected, positioning acute-phase proteins as potential biomarkers in several types of cancer ³⁶. Some members of these plasma proteins are prognostic serum/plasma biomarkers (LDH ³⁷, e.g., Serum amyloid A ^{36,38,39}), with increased expression in patients with short survival (CRP ^{36,40}, as well as ORM1 ⁴¹). Notably, all these proteins were identified as upregulated in the medium-high/high proliferative groups, which indicates a correlation to tumor cell proliferation. The observation that the main plasma proteins that discriminate between groups of tumors based on proliferation are mainly involved in biological pathways and processes related to the response of the immune system, has strong implications on the influence that melanoma exerts on the immune system, outside their physical limits.

Figure 4. Biological processes altered with increased proliferation are similar across tumor proteome, tumor transcriptome, and plasma proteome.

A) Volcano plot of the $-\log_{10}$ transformed ANOVA test p-value (FDR-corrected) and the average $\log_2$ FC_{High-Low} of the proteins, and the Gene Ontology Biological Process (GO BP) over-representation analysis of the significant proteins (FDR < 0.001). **B)** Volcano plot of the $-\log_{10}$ transformed ANOVA test p-value (FDR-corrected) and the $\log_2$ FC_{High-Low} of transcripts, as well as the GO BP over-representation analysis of the significant transcripts (FDR < 0.001). **C)** Overlap between significantly overexpressed proteins and transcripts in higher proliferation groups. **D)** sPLS-DA on melanoma plasma proteome. Ellipses delimit the sample groups created based on the proliferation status of the corresponding tumor samples. **E)** Enrichment scores for hallmark gene sets as provided by pre-ranked GSEA. The analysis provides further evidence that similar processes are up- and downregulated

with increased proliferation in both data sets. **F)** Biological pathways and processes significantly enriched in the top plasma proteins discriminating between high and low proliferation.

2.5. Study of the melanoma kinome in the context of tumor proliferation

The study of the kinome through proteomics and phosphoproteomics provided further insight into the interplay between tumor proliferation and the repressed immune system. We first explored the kinome data of our sample cohort (including non-tumor and tumor microenvironment samples) comprehensively. We identified members of each major protein kinase class, with a fairly even distribution (**Figure 5A**). Out of the 522 human kinases present in the KinMap database ⁴², we were able to directly identify 334 kinases, from which 297 and 232 were quantified in our proteomic and phosphoproteomic data respectively. Furthermore, we performed motif analysis using motifER ⁴³ on the phosphorylated peptides and found 104 enriched motifs. These are predicted to be substrates of 260 kinases, out of which 58 kinases were not experimentally identified in our study. The number of identified and predicted kinases thus reached 75% of all human kinases, which indicates that our data of the melanoma proteome and phosphoproteome can capture the majority of phosphorylation events occurring in melanoma (**Figure 5B-C**). The GMGC group is an interesting kinase family where many kinases were detected at the protein level, which we also found to be upregulated in highly proliferating tumors. This group entails cyclin-dependent kinases (CDK) as well as mitogen-activated protein kinases (MAPK), both mediators of cell proliferation ^{44,45}.

Turning our focus only to the tumor tissue samples, we were interested in the changes of kinase activities between high and low proliferating tumors. We performed kinase-substrate enrichment analysis using the KSEA App ⁴⁶⁻⁴⁹ which allows us to computationally infer the relative kinase activity based on the quantitative phosphoproteomic data. We identified 20 kinases for which at least 5 substrates were quantified in our data, and also showed altered activity (the p-value of the kinase Z-score was less than 0.15) (**Figure 5D**). Many of these kinases are well-

known to be directly or indirectly regulators of cell proliferation-related processes, as expected. Interestingly, we identified multiple kinases involved in the immune system which has been mentioned in the literature as notable players in immunotherapies. A recent study suggested that CDK1 might contribute to a mechanism that induces immune escape in hepatocellular carcinoma and could be utilized to predict the patient's response to immunotherapy ⁵⁰. Another study on SKOV3 ovarian carcinoma cells proposed that CDK2 (and CDK4) may play an important role in the proliferation-promoting effects of tumor-associated macrophages ⁵¹. mTOR is viewed as a potential oncogene in targeted immunotherapies as studies suggest that the mTOR signaling is vital in the functions of the immune cells ⁵². The GSK3 kinase (ergo its two isoforms, GSK3A and GSK3B) have been proposed to be a good candidate for immunotherapy, as its inhibitors promote an immune response against a wide range of human cancer cells, including melanoma ⁵³. The RAF kinases (ARAF, BRAF, CRAF) are intensively studied due to their role in tumorigenesis regulation, however, it was also found that they are required for the differentiation and function of dendritic cells ⁵⁴. PRKCA was shown to be involved in the proliferation and differentiation of immune cells, although its function shows both pro- and anti-oncogenic properties ⁵⁵. Moreover, PRKCA phosphorylates TRPC1 and thus regulates the Ca²⁺ entry in human endothelial cells ⁵⁶. A research study recently suggested that tumors that harbor loss-of-function PRKDC mutations, including melanoma, may benefit from immune therapy ⁵⁷. The inactivation of SGK1 can be associated with anti-oncogenic effects both on tumor cells and on the immune microenvironment and is considered a potential target in non-small cell lung cancer ⁵⁸. In summary, our kinome data suggested the importance of a couple of kinases in melanoma cell proliferation and the regulation of the immune system. To the best of our knowledge, not all kinases were previously connected to melanoma, thus, the role of these kinases at the level of immune-regulation in this particular cancer is yet to be established.

Figure 5. Kinase activities altered with increased proliferation. A) A kinome tree illustrating the wide range of kinases identified and predicted in our multi-omic study of tissue samples (including non-tumor and tumor microenvironment samples). Coloring of the branches was according to the mean log₂ FC (higher vs lower proliferation status) of the kinases. The figure was made using Coral ⁵⁹. **B)** Venn diagram indicating the number of

kinases directly identified in our proteomic and phosphoproteomic data, and the overlap between the predicted and identified kinases. **C)** The top 8 enriched motifs in the phosphoproteome. The peptide sequence motif plots were generated using MotifE. **D)** Inference of relative kinase activities between higher and lower proliferating tumors using kinase-substrate enrichment analysis. Here we show only the kinases for which at least 5 substrates were detected in the phosphoproteomic data and showed significantly altered activity (p-value of the Z-score < 0.15). The total amount of detected substrates (phosphopeptides), as well as the protein abundance change for each kinase between high and low proliferation groups (if available) is also noted. Grey colored cells represent a missing value.

2.6. Metabolic reprogramming in melanoma

The metabolic shift from oxidative phosphorylation to glycolytic phenotype has been considered an established common feature for most cancers^{60,61}. Previously, it was reported that melanoma metastases upregulate glycolysis compared to primary tumors¹⁰. Our observations confirm that melanoma shows upregulation of the glycolysis, moreover, its upregulation correlates with high proliferation (**Figure 6A-B**). The isoforms M1 and M2 of the pyruvate kinase (PKM) gene are produced by differential splicing. PKM-M1 is the main form in muscle, heart, and brain, and PKM-M2 is found in early fetal tissues as well as in most cancer cells. In melanoma we found PKM-M2 upregulated in all tumor sample groups and the tumor microenvironment, confirming the hypothesis that metabolic reprogramming in melanoma extends to the tumor microenvironment (**Figure 6C**). The upregulation of the hexokinases (HK1-3), and the Phosphoenolpyruvate

carboxykinase (PCK2) support the accumulation of intermediates of glycolysis required for cell proliferation. However, the enzymes involved in the conversion of pyruvate to Acetyl-CoA were upregulated in tumors, which indicates that part of glycolysis intermediates are directed to the TCA cycle. In addition to the glycolysis, the tumors and their microenvironment significantly upregulated the oxidative phosphorylation (OXPHOS) and the mitochondrial translation (**Figure 6D**). These findings suggest that to support their high proliferation rate, tumors rely on glycolysis and OXPHOS for the production of energy and proliferation-related intermediates. In agreement with these results, we found that most of the protein elements of the hypoxia-inducible factor 1 (HIF-1) signaling pathway were upregulated in tumors (**Figure 7A**). Consequently, the activation of the HIF-1 signaling pathway provides melanoma with a continuously proliferating activation signal, even under conditions of nutrient deprivation.

and those that show a positive correlation (red rectangle) with the melanoma progression and higher proliferation. **B)** Schematic representation of the glycolysis pathway where the proteins identified and quantified in the study were highlighted. The proteins that are marked with red and blue color show a correlation between their abundance profile and the progression of the disease (red: positive, blue: negative correlation) The protein pyruvate kinase PKM is also highlighted in pink, for which two isoforms were identified and PKM-M2 showed a strong positive correlation with the disease progression while the PKM-M1 isoform showed a weak negative correlation. **C)** Relative abundance of proteins across different sample groups. Grouping was both based on the sample origin (from Non-tumor to Distant metastasis) and based on the proliferation status (from Low to High proliferative). Selected proteins were: hexokinases 1-3 (left panels), phosphoenolpyruvate carboxykinase [GTP], mitochondrial, and isoforms M1 and M2 of the pyruvate kinase PKM (right panels). **D)** Mitochondrial oxidative phosphorylation and translation machinery pathways altered across different sample origins and proliferation groups. Proteins reported to be involved in the Oxidative phosphorylation pathway (upper panel) and those involved in mitochondrial translation (bottom panel) were plotted with their mean relative level in the groups of samples. *, **, *** and **** means significant differences between groups ($p < 0.05$, $p < 0.01$, $p < 0.001$ and $p < 0.0001$ respectively).

Moreover, the calcium signaling pathway which impacts the metabolism and the proliferation of the cell was found dysregulated in melanoma (**Figure 7B**). Proteins involved in controlling the levels of intracellular calcium showed dysregulation. Plasma membrane calcium-transporting ATPases 1, 3, and 4 (ATP2B1, ATP2B3, and ATP2B4), involved in the active release of intracellular calcium through the plasma membrane, were downregulated in the microenvironment. In the case of

ATP2B4, it was also significantly downregulated in tumor groups compared to non-tumors. On the other hand, the main intracellular calcium-binding protein, calmodulin, was upregulated in the microenvironment and all tumor sample groups compared to non-tumors (**Figure 7C**). These findings highlight the dependence of melanoma on intracellular calcium, at the level of preventing the release of calcium not only from tumor cells but also from their microenvironment.

between the protein levels and the groups of samples (see legend). **B)** Schematic representation of Calcium signaling pathway where proteins identified in the study are highlighted. Color indicates the correlation observed between the protein levels and the groups of samples (see legend). **C)** Relative levels of the ATPases 1, 3 and 4 (ATP2B1, ATP2B3 and ATP2B4) and calmodulin in groups of samples based on the origin.

2.7. Lysine acetylation in melanoma

The acetylation workflow allows not only the identification of site-specific lysine acetylation, but also of the stoichiometry impacting the melanoma staging. On average, more than 1100 peptides and 800 proteins were identified carrying acetylation marks in tumor samples, while for non-tumor and microenvironment samples the acetylated peptides and proteins were about 500 and 350 respectively (**Figure 8A**). The abundance distribution of acetylated proteins highlights the fact that with the current technology and workflow, we can detect acetylation sites and quantify their occupancy in relatively higher abundant proteins compared to the total of identified proteins (**Figure 8B**). This is a reflection of what has been previously reported, that acetylation in lysine residues is a post-translational modification that generally shows very low occupancy on their target sites^{13,62,63}. In all the samples submitted to the analysis the site-specific occupancy distribution was very similar. At least 50 % of the acetylated peptides identified in all samples, showed a stoichiometry of less than 15% (**Figure S5**), which is also highlighted after normalization of the data using probit transformation^{64,65} (**Figure 8C**).

The melanoma acetylome reported here includes about 3000 proteins, in most of them, only one acetylation site was detected. However, it was found that several proteins have multiple acetylation sites (**Figure 8D**). Particularly, the 100 topmost acetylated proteins were found with at least 7 different acetylated peptides. A functional annotation enrichment analysis of the proteins with at least 7 acetylation sites in melanoma reveals that acetylation regulates pathways involved

in the cytoskeleton, its organization, the actin filaments, and the regulation of cell shape. Besides, as previously reported, a large number of proteins from the translation machinery, the spliceosome, and metabolic enzymes were found to have multiple acetylation target sites^{66,67} (**Figure 8E**). Among the proteins with more acetylation sites in melanoma, we also found a cluster of biological annotations that includes the protein processing in the endoplasmic reticulum, and the antigen process and presentation to be significantly enriched. Particularly these pathways are among the most mutated and dysregulated in melanoma. These findings reveal an important role of lysine acetylation in the regulation of critical pathways for melanoma development and progression.

From the proteomic data, we were able to quantify in at least two-thirds of the samples 9 out of the 18 deacetylases reported in the human genome. HDAC1 and 2 from class I, HDAC4 and 7 from class IIa, HDAC6 from class IIb, and four out of the seven sirtuins or class III HDACs (SIRT2, 3, 5, and 6). The role in cancer of several members of these families has been highlighted^{68–70}. In melanoma, several clinical studies have shown benefit to the patients by targeting HDAC class I, particularly for those with acquired resistance to targeted therapy⁷¹. The combination of HDAC inhibitors with immunotherapy has shown an enhanced response to the therapy^{72,73}. Here we show that most of these enzymes, not only are upregulated in melanoma but also their abundance is higher in the more proliferative groups of tumors (**Figure 8F**). The relative level of the deacetylase enzymes in melanoma together with quantitative analysis on the site-specific acetylation targets allow a better understanding of how the treatment with HDAC or specific target inhibitors can be implemented in a personalized treatment strategy.

Figure 8. Lysine acetylome in melanoma. **A)** Identified acetylated peptides and proteins in melanoma-related tissue biopsies, distributed based on sample origin. **B)** Abundance distribution based on the sample origin of all identified proteins and those detected being acetylated. **C)** Frequency distribution of site-specific occupancy of acetylated peptides in each sample. The original values in percentage of the site modified were probit transform before plotting to fit normal distributions. **D)** Distribution of acetylated proteins based on the number of acetylated peptides identified in melanoma-related biopsies. Dashed line delimits the proteins with at least 7 different acetylated peptides in the study (122). **E)** Most targeted proteins with acetylation as a post-translational modification in melanoma are connected to their most relevant enriched functional annotation clusters. The enrichment analysis was performed in DAVID Bioinformatics ⁷⁴. **F)** Hierarchical clustering of the tissue samples based on the relative protein abundance of the nine enzymes with reported deacetylase activity, identified in at least two-thirds of the samples.

2.8. The melanoma progression involves repression of the tumor amino acid metabolism pathway and the evasion of the immune surveillance

Primary tumors, when compared to non-tumors upregulate proliferation-related pathways such as DNA replication,

ribosome biogenesis, spliceosome, and RNA transport. Oppositely, tumors downregulate a set of proteins involved in the communication with the extracellular environment and cell adhesion (Figure 9C). The changes in the metabolism of the primary tumors include downregulation of pathways linked to the degradation of amino acids and fatty acids. When compared

to non-tumors, although the tumor microenvironment samples do not show upregulation of proliferation-related pathways as primary tumors do, they show similar alterations in the pathways related to the extracellular matrix communication (**Figure 9A-C**). Interestingly, similar pathways and biological annotations of the proteins were significantly enriched in proteins dysregulated at the level of acetylation in their lysine residues. The glycolysis pathway, which upregulation has correlated with the development of melanoma, was found under-acetylated in both

primary tumors and their microenvironment compared to non-tumors. Similar results were obtained for ribosomal and translational proteins, suggesting that acetylation on those proteins could primarily have a downregulatory effect on the pathways. Oppositely, several proteins involved in the extracellular matrix and cell-cell adhesion, downregulated in primary tumors showed increased levels of acetylation (**Figure 9D-F**).

Figure 9. Dysregulated proteome and acetylome in primary melanoma and their microenvironment. Biological pathways significantly enriched when comparing the mean protein abundances between the group of samples based on their origin, according to 1D functional enrichment analysis provided by Perseus software ⁷⁵. Data is represented as volcano plots where the annotation enrichment p-value and the score of the differences were plotted. A false discovery rate (FDR) of 0.02 was set as the cut-off for significance. **A)** Comparison between the tumor microenvironment and the non-tumor samples, **B)** between the primary tumor and the tumor microenvironment, and **C)** the primary tumor and the non-tumor. **D-F)** Functional annotation clusters significantly enriched in acetylated proteins that showed significant differences in their site-specific acetylation

occupancy between origin-based groups. D) Comparison between the tumor microenvironment and the non-tumor samples, E) between the primary tumor and the tumor microenvironment, and F) the primary tumor and the non-tumor.

Among the most mutated genes in melanoma identified as hot spot, it was highlighted several members of the antigen presenting MHC class I and class II. A quantitative analysis from the proteomic data reveals that when taken together, the members of the MHC class I on average show lower level in the metastasis groups compare to both non-tumor and primary tumors, although not all the comparisons were statistically significant (**Figure 10A** (left panel)). Moreover, when analyzing only the tumor samples grouped based their proliferation groups, there is a downregulation of this proteins in relation to the proliferation. The average repression of this proteins, between the high and low proliferative groups, was found to be significant (**Figure 10A** (right panel)). Similar results were obtained from the analysis on the identified family members of the MHC class II (**Figure 10B**). These findings provide more insight into how melanoma manages to evade the immune surveillance, by heavily mutating and downregulating the antigen processing and presenting machinery, which ultimately affect the immune system response⁷⁶.

The progression of melanoma from primary lesions towards metastasis was studied through a biological pathway enrichment analysis on dysregulated proteins between metastases and

primary melanomas. Represented pathways were found significantly dysregulated in at least one of the metastasis groups compared to primary tumors (**Figure 10C**). The metabolic changes in metastatic melanoma continue with the downregulation of the amino acid metabolism, as observed in the comparison between the primary and non-tumor samples. Similarly, pathways linked to the communication with the extracellular environment, including proteins involved in cell-cell adhesion were downregulated in metastases. In this sense, the repression of amino acid metabolic and cell communication pathways is a common feature of melanoma development and progression. Additionally, one of the most relevant characteristics of metastatic melanomas compared to primary tumors is the downregulation of immune system response-related pathways (**Figure 10C**). The repression of pathways linked to the immune system is a common feature of melanoma proliferation and progression. Pathways involved in DNA replication and repair, transcription, and translation showed upregulation in the metastasis groups, mostly in cutaneous metastases. Altogether, the aggressiveness of melanoma is supported by a combined upregulation of proliferation-related pathways, rewiring of the metabolism, and repressing the immune system response.

Figure 10. Melanoma progression toward metastasis is driven by changes in the metabolism and downregulation of the immune system-related pathways. Relative levels of the identified family members of the MHC class I (A) and class II (B). Samples were grouped based on their tissue origin (left panels), and based on their proliferation status (right panels). C) Dysregulated biological KEGG pathways between the primary tumors and the different groups of metastases included in the study. The pathways were distributed according to their classification (general and specific). Bar length correspond to the $-\log_{10}$ (q-value), and the gray area correspond to non-significantly enriched. Negative and positive values correspond to down- and upregulated in the metastasis compared to the primary tumor group, respectively.

3. Discussion

In this study, we provided new insights into the progression of melanoma through a comprehensive proteogenomic analysis on primary-, and metastasis tumors, including 77 tissue-, and 56 plasma- samples from 47 melanoma patients and with various

sample origins (non-tumor, tumor microenvironment, primary tumor, local recurrence, cutaneous, lymph node, and distant metastasis). We included deep proteomics and PTM data accompanied by whole exome sequencing to provide an integrated characterization of MM. Several studies have been conducted in large melanoma cohorts using high throughput omic analyses ^{8,9,77} to gain a better understanding of the

molecular mechanism that underlies the development and progression of melanoma. We emphasize the processes that are dysregulated with increased melanoma cell proliferation. Hence, we inferred the proliferation status of each tissue sample based on the relative protein levels of the MCM complex elements. The plasma samples originating from patients with high or low proliferation tumors were also distinguishable at the plasma proteome level. Including the Skin Cutaneous Melanoma TCGA PanCancer data in the analysis, we further validated and supplemented our findings using a larger sample cohort.

Whole exome sequencing of the tumor samples highlighted that mutations occurring in melanoma stem from similar underlying molecular mechanisms in all samples. Hot spot analysis identified 132 genes with frequent somatic mutations, and notably, many members of this list were known to be interactors or regulators of the immune system, such as the MHC class I and II elements. Furthermore, the signaling cascades (MAP kinases and PI3K-AKT) and the calcium homeostasis were the most heavily dysregulated pathways due to the high mutation burden in melanoma. These observations on exome level were reaffirmed on protein level. Firstly, we systematically identified proteins and genes that indicate the suppression of the immune response throughout our analyses, both during the exploratory analysis of the tissue and plasma proteome and the TCGA data, and both during the more targeted analyses. Our findings point to a direct link between the repression of members of the MHC family by mutations or translational downregulation, and progression of melanoma. Moreover, we found this repression in correlation to tumor proliferation. The relation between immune system modulation and tumorigenesis in melanoma has been extensively studied for the past few years, as increased proliferation and lack of immunoediting go hand in hand at a more progressed stage of the disease^{78–80}. While immunotherapies are the most effective treatments for melanoma patients nowadays, far from all patients respond favorably, and there is therefore still a need for increasing our knowledge of melanoma biology to develop new therapies, strategies to overcome resistance, and increase the number of patients responding to the immunotherapeutic agents^{29,30}.

The quantitative analysis of two of the most important posttranslational modifications, the phosphorylation and lysine acetylation, deeply complements the proteomics analysis by adding elements of regulation at a level usually ignored by other large-scale analyses. Our analysis of the melanoma kinome highlighted that 75% of all human kinases were detected or predicted based on their phosphorylated targets, which allows to capture the major phosphorylation events. The kinase-substrate analysis outlined multiple kinases that are activated or deactivated with increased proliferation. Moreover, several of these kinases are considered potential therapeutic targets due to their role in the function of the immune system, such as the GSK3A kinases or the SGK1. Additionally, to the best of our knowledge, this is the first lysine acetylome stoichiometry analysis reported for a large number of melanoma tumor

samples. Our observations highlight that the translation machinery and metabolic enzymes are regulated by acetylation and as a general trend lower acetylation degree resulted in upregulation of the pathway. This is particularly interesting because several of the deacetylase enzymes identified in the study were indeed upregulated in melanoma. Our findings support previous reports that HDAC inhibitors treatment in melanoma particularly in combination with immunotherapy enhance the response of the patients^{72,73,81}.

We found that both glycolysis and OXPHOS are utilized by highly proliferating melanoma cells to produce energy and the proliferation-related intermediates, supported by the observed activation of the HIF-1 signaling pathway, leading to continued proliferation even in the event of nutrient deficit. We further characterized melanoma by the downregulation of proteins involved controlling the levels of intracellular calcium, the repression of amino acid metabolism, and the suppression of cell communication. The observed metabolic reprogramming extended to the tumor microenvironment, but was not discovered in non-tumor samples.

We acknowledge the limitations of our study. An experimental design involving samples from 7 different tissue origins is ultimately more prone to bias due to the low sample sizes within each sub-cohort. Nonetheless, the integration of genetic level information and PTM data next to proteomics represents a rich resource to investigate melanoma biology, and main observations from one type of omic data were supplemented on another molecular layer, thus confirming the validity of our results. We envision that the hypotheses underlined in this manuscript will contribute to a better understanding of melanoma and will aid the development of new therapies.

4. Experimental section

4.1. Sample processing and peptide/protein identification

A protein extraction buffer containing SDS 2%, DTT 50 mM, Tris 100 mM, pH 8.6, was added to the sliced tissues or cell pellet, rest for one minute, and sonicated using a Bioruptor plus (40 cycles, 15 s On, 15 s Off, at 4 °C). Samples were incubated at 95 °C for 5 min. Proteins were alkylated by adding IAA to a final concentration of 100 mM for 20 min in the dark at room temperature (RT). The proteins were precipitated overnight by adding 9 volumes of cold ethanol. Proteins were dissolved in TEAB buffer containing SDS 1%, SDC 0.5%, and submitted to a chemical acetylation reaction of all free amino groups. The reaction was performed with N-acetoxy-succinimide-d3 (NAS-d3). O-acetylation was reverted by treating the samples with 5% hydroxylamine. Proteins were precipitated as described above to remove the excess reagents and dissolved in AmBiC containing SDC 0.5%. Proteins were digested with trypsin (1:50, enzyme:protein) at 37 °C, overnight. The SDC was removed from

the peptide solution by adding ethyl-acetate and TFA ¹³. After discarding the organic phase, the mixtures of peptides were quantified and kept at -80 °C until MS analysis.

For phosphopeptide enrichment, 80 mg of peptides was submitted to an automated workflow, performed on an AssayMAP Bravo system (Agilent Technologies). The procedure was performed as previously described ¹¹. Phosphopeptides were dried and kept at -80 °C until MS analysis.

Peptide spectral library: Pools of peptides including all the tumor samples were spiked with iRT and analyzed in a high-resolution LC-MS system (Dionex Ultimate 3000 RSLCnano UPLC coupled to a Q-Exactive HF-X mass spectrometer (Thermo Fischer Scientific)). Peptides were desalted on a trap column Acclaim PepMap100 C18 (3 µm, 100 Å, 75 µm i.d. × 2 cm, nanoViper) and then connected in line with an analytical column EASY-spray RSLC C18 (2 µm, 100 Å, 75 µm i.d. × 50 cm). The temperature of the trap column and analytical column was set at 35 °C and 60 °C respectively, and the flow rate was 300 nL/min. A non-linear gradient of 137 min was used for peptide elution. Data were acquired applying a DDA method covering a mass range of 385-1460 m/z. The parameters for MS1 included a resolution of 120,000 (@ 200 m/z), the target AGC value of 3·10⁶, and the maximum injection time was set at 100 ms. For MS2, the resolution was 15,000, the AGC value 1·10⁵, the injection time 50 ms, the threshold for ion selection 8·10³, and the normalized collision energy (NCE) 28. The isolation window was 1.2 Th.

DIA analysis: samples were analyzed in duplicates using the same LC-MS system and with the same chromatographic conditions as described above. Data were acquired using a DIA method intended for peptide quantification using MS1 scans. The DIA method contains 54 variable width MS2 windows, based on the empirical distribution of peptides, and 3 full scan MS1. A full MS1 scan was placed every 18 MS2 scans. The parameters for MS1 were: resolution 120,000 (@200 m/z), AGC target 3E+06, injection time 50 ms, range 385-1460 Th. For the MS2 were: resolution 30,000, AGC target 1·10⁶, injection time 50 ms, NCE 28.

Protein and peptide identification and quantification were performed with the Spectronaut software (Biognosys, AG). DDA raw files were searched against a human protein database downloaded from UniProt in 2018, to create a spectral library. The search engine used was pulsar, which is integrated into the Spectronaut platform. The parameters included Arg-C as the cleavage enzyme, 2 missed cleavages were allowed, lysine acetylation (d3) and carbamidomethyl-cysteine were set as fix modifications, methionine oxidation and protein N-terminal acetylation (d3) and (d0) were set as variable modifications. For the postmortem cohort, the selected enzyme was trypsin, two missed cleavages were allowed, carbamidomethyl-cysteine was fixed, and methionine oxidation and protein N-terminal acetylation were set as a variable. The identifications were

controlled by an FDR of 1% at the PSM, peptide, and protein levels.

For identification and quantification of lysine acetylation, raw files were analyzed by two different software Pview ⁸² and Proteome discoverer (Thermo scientific). Acetylation stoichiometry was only considered for those peptides commonly identified by the two search engines. The parameters included Arg-C as the cleavage enzyme, carbamidomethyl cysteine as fix modification, methionine oxidation, and lysine acetylation (d0 and d3) were set as variable modifications. The number of identifications was controlled by FDR of 1% at peptide and protein level. The parameters for the stoichiometry calculation were as previously reported ¹³. For comparison of the acetylation occupancy between groups, a probit transformation of the data was applied.

4.2. Proteomic, phosphoproteomic, and transcriptomic data processing, statistics, and bioinformatics

The data processing and statistics were performed in R (vs. 4.0) unless specified otherwise. The Skin Cutaneous Melanoma TCGA PanCancer data ^{9,83,84} was downloaded from the cBioPortal website ^{85,86}.

A similar data pre-processing workflow was applied on protein and phosphopeptide intensities as well as on the transcriptome data. For the RNA expressions, counts equal to 0 were treated as NA values. Intensities/counts were log₂ transformed, followed by global median centering for normalization, and sample replicates averaging in case of the proteomic data. The correlation in abundance between proteins from the MCM protein complex was used as a criterion to evaluate the normalization performance. Differential expression analysis was performed using Analysis of Variance (ANOVA test), followed by ANOVA p-value adjustment with the Benjamini-Hochberg method and an additional Tukey-Kramer post hoc test for each ANOVA analysis. No prior filter for valid values was applied on either data set, however, only those groups were compared where the protein/phosphopeptide/gene had valid values in at least 70% of the groups' samples. Comparison between proteomic and transcriptomic signatures related to proliferation status was done using Gene Set Enrichment Analysis (GSEA) on the 50 hallmark gene sets that were downloaded from <http://www.gsea-msigdb.org/gsea/msigdb/index.jsp>. The ordered list of mean log₂ FC values across the proliferation groups was used as the input and no p-value threshold was set. The hallmark gene sets were further categorized according to Liberzon et al. ⁸⁷. Gene Ontology over-representation test on the biological processes and Gene Set Enrichment Analysis was performed using the R package "clusterProfiler" (vs. 3.18.1).

Kinome analysis: The list of human kinases was downloaded from <http://www.kinohub.org/kinases.html> (on 10 March 2021).

Sequence pre-alignment and motif analyses were done using the motifER web server (<https://www.omicsolution.org/wukong/motifeR/>). In this analysis, we included only the phosphopeptides that were identified in at least 30% of the samples and where the phosphorylation site was confidently identified (8994 sequences). Sequence data were aligned to have 15-amino-acid long sequences where the central residue is the phosphorylated S/T amino acid. For the motif analysis, the following settings were applied: each motif had to appear at least 20 times in the data set, and the p-value threshold for the binomial probability was set to 1e-06 for the selection of significant residues in the motif. The default human database was used as a background and classical multiple sites analysis was chosen. Motif enrichment analysis was done both on peptides with one and with multiple modification sites. Kinases were predicted based on all the enriched motifs and the minimum NetworkKin score was set to 3.

Kinase-substrate enrichment analysis was performed using the KSEAapp R package. Both curated annotations from PhosphoSitePlus and kinase-substrate predictions from NetworkKIN were considered (Kinase-Substrate dataset downloaded from the KSEAapp Github page <https://github.com/casecpb/KSEA>), and the minimum NetworkKIN score was set to 5.

5. Acknowledgments

This study was kindly supported by the Berta Kamprad Foundation, Thermo Fischer Scientific as our strategic partner, The Swedish Pharmaceutical Society and Agilent Technologies. This work was done under the auspices of a Memorandum of Understanding between the European Cancer Moonshot Center in Lund and the U.S. National Cancer Institute's International Cancer Proteogenome Consortium (ICPC)

6. References

1. IARC. Latest Global Cancer Data, 2018. *World Heal. Organ.* (2018).
2. Leonardi, G. C. *et al.* Cutaneous melanoma: From pathogenesis to therapy (Review). *International Journal of Oncology* (2018) doi:10.3892/ijo.2018.4287.
3. Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature* (2013) doi:10.1038/nature12477.
4. Gara, S. K. *et al.* Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors. *Nat. Commun.* **9**, 4172 (2018).
5. Szász, A. M., Gyórfy, B. & Marko-Varga, G. Cancer heterogeneity determined by functional proteomics. *Semin. Cell Dev. Biol.* **64**, 132–142 (2017).
6. Betancourt, L. H. *et al.* The hidden story of heterogeneous B-raf V600E mutation quantitative protein expression in metastatic melanoma—association with clinical outcome and tumor phenotypes. *Cancers (Basel)*. **11**, 1981 (2019).

4.3. WES analysis

WES data analysis: The WES sequencing data of the 60 samples were mapped against GRCh38 and analyzed according to standard workflows as described by GATK (Broad Institute). Additional filtering was applied to remove variants with coverage of less than 3 reads. Next, the exome panel enrichment regions from Twist Bioscience (downloaded from [https://www.twistbioscience.com/sites/default/files/resources/2019-06/Twist Exome Target hg38.bed](https://www.twistbioscience.com/sites/default/files/resources/2019-06/Twist%20Exome%20Target%20hg38.bed)) were used to filter out all identified variants outside of these WES targeted regions. The non GCTA nonTCGA_gnomAD subset was used as “population background” information to distinguish between variants annotated in this database referred to as germline and those missing (referred to as somatic variants). Summary statistics about the variants in each of these 2 categories were created using the “bcftools stats” utility.

Hot spot analysis: The somatic and germline variant counts were grouped and summed by the gene they overlap with. Chi-square tests were performed to determine genes within individual samples for which the number of somatic variants was different than expected based on the sample's ratio of these counts across all genes. Similarly, the variant counts per gene were grouped and summed on a pathway level. Bonferroni correction was applied on the obtained p-values. Genes with significant enrichment were selected by using the significance level 0.05 and requiring the presence of significant enrichment in 1/3 of the data (20 out of 60 samples). Data visualization and final statistics were made with a custom R script.

7. Dimitriou, F. *et al.* The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. *Current Oncology Reports* (2018) doi:10.1007/s11912-018-0732-8.
8. Harel, M. *et al.* Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence. *Cell* (2019) doi:10.1016/j.cell.2019.08.012.
9. Akbani, R. *et al.* Genomic Classification of Cutaneous Melanoma. *Cell* (2015) doi:10.1016/j.cell.2015.05.044.
10. Gil, J. *et al.* Clinical protein science in translational medicine targeting malignant melanoma. *Cell Biol. Toxicol.* **35**, 293–332 (2019).
11. Murillo, J. R. *et al.* Automated phosphopeptide enrichment from minute quantities of frozen malignant melanoma tissue. *PLoS One* (2018) doi:10.1371/journal.pone.0208562.
12. Adhikari, S. *et al.* A high-stringency blueprint of the human proteome. *Nature Communications* (2020) doi:10.1038/s41467-020-19045-9.
13. Gil, J. *et al.* Lysine acetylation stoichiometry and proteomics analyses reveal pathways regulated by sirtuin 1 in human cells. *J. Biol. Chem.* **292**, 18129–18144 (2017).

14. Das, M., Singh, S., Pradhan, S. & Narayan, G. MCM Paradox: Abundance of Eukaryotic Replicative Helicases and Genomic Integrity. *Mol. Biol. Int.* **2014**, 574850 (2014).
15. You, Z., Komamura, Y. & Ishimi, Y. Biochemical Analysis of the Intrinsic Mcm4-Mcm6-Mcm7 DNA Helicase Activity. *Mol. Cell. Biol.* (1999) doi:10.1128/mcb.19.12.8003.
16. Lee, J. K. & Hurwitz, J. Processive DNA helicase activity of the minichromosome maintenance proteins 4, 6, and 7 complex requires forked DNA structures. *Proc. Natl. Acad. Sci. U. S. A.* (2001) doi:10.1073/pnas.98.1.54.
17. Miller, T. C. R., Locke, J., Greiwe, J. F., Diffley, J. F. X. & Costa, A. Mechanism of head-to-head MCM double-hexamer formation revealed by cryo-EM. *Nature* (2019) doi:10.1038/s41586-019-1768-0.
18. Cao, T. *et al.* Identification of the DNA Replication Regulator MCM Complex Expression and Prognostic Significance in Hepatic Carcinoma. *Biomed Res. Int.* (2020) doi:10.1155/2020/3574261.
19. Issac, M. S. M., Yousef, E., Tahir, M. R. & Gaboury, L. A. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. *Neoplasia (United States)* (2019) doi:10.1016/j.neo.2019.07.011.
20. Valverde, L. D. F. *et al.* MCM3: A Novel Proliferation Marker in Oral Squamous Cell Carcinoma. *Appl. Immunohistochem. Mol. Morphol.* (2018) doi:10.1097/PAI.0000000000000397.
21. Stojkovic-Filipovic, J., Brasanac, D., Bosic, M. & Lekic, B. Minichromosome maintenance protein expression in squamous cell carcinoma. *Melanoma Res.* (2016).
22. Aporowicz, M. *et al.* Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors. *Anticancer Res.* (2019) doi:10.21873/anticancer.13224.
23. Wojnar, A. *et al.* Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. *Folia Histochem. Cytobiol.* (2010) doi:10.2478/v10042-010-0069-0.
24. Giaginis, C. *et al.* MCM-2 and MCM-5 expression in gastric adenocarcinoma: Clinical significance and comparison with Ki-67 proliferative marker. *Dig. Dis. Sci.* (2011) doi:10.1007/s10620-010-1348-5.
25. Giaginis, C. *et al.* Clinical significance of MCM-2 and MCM-5 expression in colon cancer: Association with clinicopathological parameters and tumor proliferative capacity. *Dig. Dis. Sci.* (2009) doi:10.1007/s10620-008-0305-z.
26. Güzel, C. *et al.* Proteomic alterations in early stage cervical cancer. *Oncotarget* (2018) doi:10.18632/oncotarget.24773.
27. Chung, D. & Keles, S. Sparse partial least squares classification for high dimensional data. *Stat. Appl. Genet. Mol. Biol.* **9**, 17 (2010).
28. Zhu, J. & Thompson, C. B. Metabolic regulation of cell growth and proliferation. *Nature Reviews Molecular Cell Biology* (2019) doi:10.1038/s41580-019-0123-5.
29. Passarelli, A., Mannavola, F., Stucci, L. S., Tucci, M. & Silvestris, F. Immune system and melanoma biology: A balance between immunosurveillance and immune escape. *Oncotarget* **8**, 106132–106142 (2017).
30. Karachaliou, N. *et al.* Melanoma: Oncogenic drivers and the immune system. *Ann. Transl. Med.* **3**, 1–22 (2015).
31. Leblanc, R. & Peyruchaud, O. Metastasis: New functional implications of platelets and megakaryocytes. *Blood* **128**, 24–31 (2016).
32. Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis 06 Biological Sciences 0601 Biochemistry and Cell Biology. *J. Hematol. Oncol.* **11**, 1–15 (2018).
33. Becker, K. A. *et al.* Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets. *Clin. Exp. Metastasis* **34**, 25–35 (2017).
34. Boukerche, H. *et al.* Platelet-melanoma cell interaction is mediated by the glycoprotein IIb-IIIa complex. *Blood* **74**, 658–663 (1989).
35. Botti, G. *et al.* Microenvironment and tumor progression of melanoma: New therapeutic perspectives. *J. Immunotoxicol.* **10**, 235–252 (2013).
36. Shannon, W., H., L., J., R. & A., J. Acute Phase Proteins as Cancer Biomarkers. *Acute Phase Proteins as Early Non-Specific Biomarkers Hum. Vet. Dis.* (2011) doi:10.5772/25181.
37. Karagiannis, P., Fittall, M. & Karagiannis, S. N. Evaluating biomarkers in melanoma. *Front. Oncol.* **4**, 1–11 (2015).
38. Findeisen, P. *et al.* Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. *J. Clin. Oncol.* **27**, 2199–2208 (2009).
39. Malle, E., Sodin-Semrl, S. & Kovacevic, A. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. *Cell. Mol. Life Sci.* **66**, 9–26 (2009).
40. Fang, S. *et al.* C-reactive protein as a marker of melanoma progression. *J. Clin. Oncol.* **33**, 1389–1396 (2015).
41. Betancourt, L. H. *et al.* Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. *Sci. Rep.* (2019) doi:10.1038/s41598-019-41625-z.
42. Eid, S., Turk, S., Volkamer, A., Rippmann, F. & Fulle, S. Kinmap: A web-based tool for interactive navigation through human kinome data. *BMC Bioinformatics* (2017) doi:10.1186/s12859-016-1433-7.
43. Wang, S. *et al.* motifER: An Integrated Web Software for Identification and Visualization of Protein Posttranslational Modification Motifs. *Proteomics* (2019) doi:10.1002/pmic.201900245.
44. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. *Nature Reviews Cancer* (2009) doi:10.1038/nrc2602.
45. Braicu, C. *et al.* A comprehensive review on MAPK: A promising therapeutic target in cancer. *Cancers* (2019) doi:10.3390/cancers11101618.
46. Wiredja, D. D., Koyutürk, M. & Chance, M. R. The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics. *Bioinformatics* (2017) doi:10.1093/bioinformatics/btx415.
47. Casado, P. *et al.* Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells. *Science Signaling* (2013) doi:10.1126/scisignal.2003573.
48. Hornbeck, P. V. *et al.* PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. *Nucleic Acids Res.* (2015) doi:10.1093/nar/gku1267.
49. Horn, H. *et al.* KinomeXplorer: An integrated platform for kinome biology studies. *Nature Methods* (2014) doi:10.1038/nmeth.2968.
50. Zou, Y. *et al.* CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. *Med. Sci. Monit.* (2020) doi:10.12659/MSM.925289.
51. Yang, Y. *et al.* CDK2 and CDK4 play important roles in promoting the proliferation of SKOV3 ovarian carcinoma cells induced by tumor-associated macrophages. *Oncol. Rep.* (2014) doi:10.3892/or.2014.3127.
52. Jin, J. & Zhao, Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. *Theranostics* (2020) doi:10.7150/thno.45219.
53. Augello, G. *et al.* The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. *Cells* (2020) doi:10.3390/cells9061427.
54. Riegel, K. *et al.* RAF kinases are stabilized and required for dendritic cell differentiation and function. *Cell Death Differ.* (2020) doi:10.1038/s41418-019-0416-4.
55. Black, A. R. & Black, J. D. The complexities of PKCα signaling in cancer. *Adv. Biol. Regul.* (2021) doi:10.1016/j.jbior.2020.100769.

56. Ahmmed, G. U. *et al.* Protein kinase Ca phosphorylates the TRPC1 channel and regulates store-operated Ca²⁺ entry in endothelial cells. *J. Biol. Chem.* (2004) doi:10.1074/jbc.M313975200.
57. Tan, K. T. *et al.* PRKDC: New biomarker and drug target for checkpoint blockade immunotherapy. *J. Immunother. Cancer* (2020) doi:10.1136/jitc-2019-000485.
58. Guerriero, I., Monaco, G., Coppola, V. & Orlacchio, A. Serum and glucocorticoid-inducible kinase 1 (Sgk1) in nslc therapy. *Pharmaceuticals* (2020) doi:10.3390/ph13110413.
59. Metz, K. S. *et al.* Coral: Clear and Customizable Visualization of Human Kinome Data. *Cell Syst.* (2018) doi:10.1016/j.cels.2018.07.001.
60. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* (2011) doi:10.1016/j.cell.2011.02.013.
61. Danhier, P. *et al.* Cancer metabolism in space and time: Beyond the Warburg effect. *Biochim. Biophys. Acta - Bioenerg.* (2017) doi:10.1016/j.bbabo.2017.02.001.
62. Narita, T., Weinert, B. T. & Choudhary, C. Functions and mechanisms of non-histone protein acetylation. *Nature Reviews Molecular Cell Biology* (2019) doi:10.1038/s41580-018-0081-3.
63. Hansen, B. K. *et al.* Analysis of human acetylation stoichiometry defines mechanistic constraints on protein regulation. *Nat. Commun.* (2019) doi:10.1038/s41467-019-09024-0.
64. Singh, N. K. *et al.* In vitro assessment of the acaricidal activity of Piper longum, Piper nigrum, and Zingiber officinale extracts against Hyalomma anatolicum ticks. *Exp. Appl. Acarol.* (2017) doi:10.1007/s10493-017-0113-2.
65. Alamir, A. E., Nenaah, G. E. & Hafiz, M. A. Mathematical probit and logistic mortality models of the Khapra beetle fumigated with plant essential oils. *Math. Biosci. Eng.* (2015) doi:10.3934/mbe.2015.12.687.
66. Choudhary, C. *et al.* Lysine acetylation targets protein complexes and co-regulated major cellular functions. *Science* (80-.). **325**, 834–840 (2009).
67. Norris, K. L., Lee, J. Y. & Yao, T. P. Acetylation Goes Global: The Emergence of Acetylation Biology. *Science Signaling* (2009) doi:10.1126/scisignal.297pe76.
68. Gil, J., Ramírez-Torres, A. & Encarnación-Guevara, S. Lysine acetylation and cancer: A proteomics perspective. *Journal of Proteomics* (2017) doi:10.1016/j.jprot.2016.10.003.
69. Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R. & Marins, M. Roles of histone deacetylases and inhibitors in anticancer therapy. *Cancers* (2020) doi:10.3390/cancers12061664.
70. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. *Nature Reviews Genetics* (2009) doi:10.1038/nrg2485.
71. Wang, L. *et al.* An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. *Cell* (2018) doi:10.1016/j.cell.2018.04.012.
72. Booth, L., Roberts, J. L., Poklepovic, A., Kirkwood, J. & Dent, P. HDAC inhibitors enhance the immunotherapy response of melanoma cells. *Oncotarget* (2017) doi:10.18632/oncotarget.17950.
73. Woods, D. M. *et al.* HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. *Cancer Immunol. Res.* (2015) doi:10.1158/2326-6066.CIR-15-0077-T.
74. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res.* (2009) doi:10.1093/nar/gkn923.
75. Cox, J. & Mann, M. 1D and 2D annotation enrichment: a statistical method integrating quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics* (2012) doi:10.1186/1471-2105-13-S16-S12.
76. Yoshihama, S. *et al.* NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc. Natl. Acad. Sci. U. S. A.* (2016) doi:10.1073/pnas.1602069113.
77. Hugo, W. *et al.* Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* (2016) doi:10.1016/j.cell.2016.02.065.
78. Lee, J. H. *et al.* Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. *Nat. Commun.* (2020) doi:10.1038/s41467-020-15726-7.
79. Ghorani, E. *et al.* Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. *Ann. Oncol.* (2018) doi:10.1093/annonc/mdx687.
80. Newell, F. *et al.* Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. *Nat. Commun.* (2019) doi:10.1038/s41467-019-11107-x.
81. Banik, D., Moufarrij, S. & Villagra, A. Immunoepigenetics combination therapies: An overview of the role of HDACs in cancer immunotherapy. *International Journal of Molecular Sciences* (2019) doi:10.3390/ijms20092241.
82. Baeza, J. *et al.* Stoichiometry of site-specific lysine acetylation in an entire proteome. *J. Biol. Chem.* (2014) doi:10.1074/jbc.M114.581843.
83. Hoadley, K. A. *et al.* Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell* (2018) doi:10.1016/j.cell.2018.03.022.
84. Ellrott, K. *et al.* Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst.* (2018) doi:10.1016/j.cels.2018.03.002.
85. Cerami, E. *et al.* The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* (2012) doi:10.1158/2159-8290.CD-12-0095.
86. Gao, J. *et al.* Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* (2013) doi:10.1126/scisignal.2004088.
87. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst.* (2015) doi:10.1016/j.cels.2015.12.004.

Figure S1. The ratio of various base-pair changes in somatic (A) and germline (B) SNPs compared to population reference (gnomAD_only excluding mutations identified in all tumor samples). The pattern is highly reproducible for both cases with difference between somatic and germline SNPs (A and B).

Figure S2. Distribution of sequence length shortening or extension of indels with somatic (A) and germline (B) origin. Somatic indels tend to extend, while germline indels generally shorten exons and protein variants. Y axis show the range of ± 15 base pair lengths.

Figure S3. Sequence coverage of somatic (A) and germline (B) mutations below 500 reads. log2 ratio of several variants with more than 500 reads and less than 500 reads is somatic and germline mutations (C) in WES data of 60 tumor samples indicating the lower sequence coverage of somatic mutations compared to the germline.

Figure S4. Manhattan plots showing the enrichment of somatic mutations compared to germline in 6 tumor samples shown as examples. Low p-values (i.e., a high $-\log_{10}(p\text{-value})$) indicate a high mutation load of genes at a given chromosomal location (x-axis), indicating a hot spot. Genes found to be significant in at least $\frac{1}{3}$ of the 60 samples were selected as a hotspot in this study and are listed in Table S3. All sample shows a peak in chromosome 6 corresponding to the HLA region.

Figure S5. Distribution of the lysine acetylation stoichiometry in the percentage of occupancy of the target site, in all the solid biopsies enrolled in the study. The dashed line indicates a site-specific acetylation occupancy of less than 15%.

8. Supplementary Tables

Table S1. Relevant information of the patients and samples.

Patient Code	Age diagnosis	Gender	Pathological stage	Primary Tumor Type	Braf Mutation Status	Sample	Origin	Proliferation status	Tumor cell (%)	Immune cells (%)	Metastasis treatment
P002	60	Female	PT4B	ALM	V600K	CM002	Cutaneous metastasis	Medium-High	56.72	0.67	YES
P003	75	Female	PT3B	SSM	WT	LR003	Local recurrence	Low	16.95	0.65	NO
P003	75	Female	PT3B	SSM	WT	LR024	Local recurrence	High	13.49	0.76	NO
P004	64	Male	PT3A	NM	V600E	LR075	Local recurrence	High	58.83	0	YES
P004	64	Male	PT3A	NM	V600E	CM004	Cutaneous metastasis	Medium-High	43.02	0.01	YES
P005	81	Female	N/A	N/A	N/A	TM005	Tumor microenvironment	Low	1	0.01	N/A
P005	81	Female	PT3A	SSM	WT	LR005	Cutaneous metastasis	Low	12.6	3.6	NO
P007	74	Female	N/A	N/A	N/A	TM071	Tumor microenvironment	Low	2	53.85	N/A
P007	74	Female	PT4A	UNCLASS	V600K	PT007	Primary tumor	Low	24.57	0.001	N/A
P007	74	Female	PT4A	UNCLASS	V600K	LN071	Lymph node metastasis	Medium-Low	N/A	N/A	NO
P008	67	Female	PT3A	NM	WT	LR008	Local recurrence	Medium-High	26.37	1.34	YES
P008	67	Female	PT3A	NM	WT	CM153	Cutaneous metastasis	Medium-Low	48.01	6.37	YES
P014	67	Male	N/A	N/A	V600E	CM014	Cutaneous metastasis	High	86.50	0.03	NO
P027	69	Male	PT4B	ALM	WT	PT027	Primary tumor	Low	24.19	0.02	N/A
P028	25	Male	PT4B	NM	V600E	PT028	Primary tumor	Medium-High	29.69	0.05	N/A
P028	25	Male	PT4B	NM	V600E	LN090	Lymph node metastasis	Medium-Low	20.52	56.08	NO
P029	83	Female	N/A	N/A	N/A	TM029	Tumor microenvironment	Low	0	0.10	N/A
P029	83	Female	PT1A	SSM	V600E	PT029	Primary tumor	Medium-Low	26	13.4	N/A
P033	71	Male	PT2B	N/A	V600K	LN033	Lymph node metastasis	Low	13.25	20.38	NO
P034	40	Female	PT4B	NM	WT	CM034	Cutaneous metastasis	High	67.49	0.10	NO
P036	59	Male	N/A	SSM	WT	DM036	gallbladder metastasis	Medium-High	30.59	0.80	YES
P037	63	Female	N/A	NM	V600E	LN037	Lymph node metastasis	High	17.36	16.14	NO
P039	84	Male	N/A	N/A	N/A	NT039	Non-tumor	Low	0	0	N/A
P039	84	Male	PT3A	ALM	WT	PT039	Primary tumor	Low	48.53	0.436871032	N/A
P041	81	Male	N/A	N/A	N/A	NT046	Non-tumor	Low	0	0	N/A
P041	81	Male	N/A	N/A	N/A	TM046	Tumor microenvironment	Low	2	0	N/A
P041	81	Male	PT3A	UNCLASS	V600E	PT041	Primary tumor	High	44.24	0.41	N/A
P041	81	Male	PT2A	SSM	V600E	PT046	Primary tumor	Medium-Low	12.41	0.04	N/A
P044	80	Male	N/A	N/A	N/A	NT044	Non-tumor	Low	0	0	N/A
P044	80	Male	N/A	SSM	V600K	PT044	Primary tumor	Medium-Low	39.57	0.51	N/A
P048	68	Female	N/A	N/A	N/A	NT048	Non-tumor	Low	0	0	N/A
P048	68	Female	PT4B	SSM	V600E	PT048	Primary tumor	Medium-High	68.07	0.011	N/A
P050	73	Male	PT4B	UNCLASS	WT	PT050	Primary tumor	High	40.57	0	N/A
P050	73	Male	PT4B	UNCLASS	WT	LN079	Lymph node metastasis	High	19.17	36.59	NO
P054	70	Female	N/A	N/A	N/A	NT054	Non-tumor	Low	0	0	N/A
P054	70	Female	N/A	N/A	N/A	TM054	Tumor microenvironment	Low	2	0.03	N/A
P054	70	Female	PT3B	SSM	V600E	PT054	Primary tumor	Medium-Low	32.2	14.4	N/A
P056	67	Female	N/A	N/A	N/A	NT056	Non-tumor	Low	0	0	N/A
P056	67	Female	N/A	N/A	N/A	TM083	Tumor microenvironment	Low	N/A	N/A	N/A
P056	67	Female	PT3B	UNCLASS	V600E	PT056	Primary tumor	High	26.03	4.80	N/A
P056	67	Female	PT3B	UNCLASS	V600E	LN083	Lymph node metastasis	Low	1.67	6	NO
P057	66	Female	PT3B	UNCLASS	V600K	LN057	Lymph node metastasis	Medium-High	27.67	4.87	YES
P059	39	Female	N/A	N/A	WT	LN059	Lymph node metastasis	Medium-High	18.90	1.52	NO
P060	89	Female	N/A	N/A	N/A	NT060	Non-tumor	Low	0	0	N/A
P060	89	Female	N/A	NM	WT	LR060	Local recurrence	Medium-Low	31.65	2.40	NO
P062	69	Male	PT4B	NM	V600E	LN062	Lymph node metastasis	Medium-High	52.17	0.96	NO
P063	75	Male	PT2B	SSM	WT	LR063	Local recurrence	Medium-High	38.10	0	NO
P066	71	Male	N/A	N/A	N/A	NT066	Non-tumor	Low	0	0	N/A
P066	71	Male	PT3A	UNCLASS	V600E	CM066	Cutaneous metastasis	Medium-High	49.01	0.21	YES
P068	75	Female	N/A	N/A	N/A	NT068	Non-tumor	Low	0	0	N/A
P068	75	Female	PT4B	NM	V600E	PT068	Primary tumor	Medium-High	32.02	0.32	N/A
P069	53	Female	PT2A	N/A	V600E	LN069	Lymph node metastasis	Medium-High	51.69	0.13	NO
P073	58	Male	N/A	N/A	WT	LN073	Lymph node metastasis	High	83.72	0.004	NO
P074	80	Male	N/A	ALM	N/A	LN074	Lymph node metastasis	Medium-High	31.43	0.06	YES
P076	64	Male	N/A	N/A	N/A	LN076	Lymph node metastasis	Medium-Low	47.19	17.62	NO
P078	43	Male	N/A	SSM	WT	DM078	Brain metastasis	Low	23.15	0	YES
P080	39	Male	PT3B	ALM	V600E	LN080	Lymph node metastasis	Low	20.33	4.38	NO
P081	69	Male	N/A	UNCLASS	V600E	LN081	Lymph node metastasis	Medium-Low	36.99	10.71	YES
P082	48	Male	PT4A	NM	WT	PT082	Primary tumor	Medium-High	46.94	0.63	N/A
P082	48	Male	PT4A	NM	WT	LN092	Lymph node metastasis	Medium-High	75.22	0.30	NO
P087	23	Male	N/A	N/A	V600E	LN087	Lymph node metastasis	Low	47.69	0	YES
P087	23	Male	N/A	N/A	V600E	DM087	Liver metastasis	Medium-High	65.37	0	YES
P089	44	Female	PT4B	ALM	WT	PT089	Primary tumor	Low	41.94	0	N/A
P089	44	Female	PT4B	ALM	WT	LN093	Lymph node metastasis	Medium-High	46.59	14.24	NO
P091	75	Male	PT4B	NM	V600E	LN091	Lymph node metastasis	High	20.94	3.82	YES
P096	66	Male	N/A	NM	V600K	CM096	Cutaneous metastasis	Medium-High	30.62	12.70	NO
P098	75	Male	N/A	N/A	N/A	LN098	Lymph node metastasis	Medium-High	35.09	23.38	YES
P100	67	Male	N/A	NM	V600E	LN100	Lymph node metastasis	Medium-Low	49.42	6.06	NO
P107	75	Male	PT3A	UNCLASS	V600K	LN185	Lymph node metastasis	Medium-Low	35.59	0.08	YES

P107	75	Male	PT3A	UNCLASS	V600K	DM107	Spleen metastasis	Medium-High	47.70	8.67 YES
P110	81	Female	N/A	N/A	N/A	NT110	Non-tumor	Medium-Low	0	0 N/A
P110	81	Female	PT3B	SSM	V600K	PT110	Primary tumor	Medium-High	44.01	3.57 N/A
P110	81	Female	PT3B	SSM	V600K	LN146	Lymph node metastasis	Medium-High	52.96	17.27 NO
P115	82	Female	N/A	N/A	N/A	NT115	Non-tumor	Medium-Low	0	0 N/A
P115	82	Female	N/A	N/A	WT	CM115	Cutaneous metastasis	Medium-Low	71.49	3.17 NO
P116	47	Female	N/A	UNCLASS	WT	DM116	Breast metastasis	Medium-Low	29.47	1 YES
P164	51	Male	N/A	SSM	V600E	CM164	Cutaneous metastasis	High	26.13	6.03 NO

Table S2 Summary of average ($\pm$ standard variation) of variants (SNPs, indels) identified in WES data of 60 tumors.

Type of mutations	Somatic	Germline
SNPs A>C and T>G	4361 $\pm$ 716	872 $\pm$ 29
SNPs A>G and T>C	4573 $\pm$ 635	6104 $\pm$ 119
SNPs A>T and T>A	11681 $\pm$ 1916	738 $\pm$ 41
SNPs C>A and G>T	9497 $\pm$ 1622	1158 $\pm$ 62
SNPs C>G and G>C	5585 $\pm$ 888	1325 $\pm$ 42
SNPs C>T and G>A	10479 $\pm$ 1593	8818 $\pm$ 299
All SNPs	46177 $\pm$ 7162	19015 $\pm$ 547
indels	57423 $\pm$ 10369	256 $\pm$ 19
All variants	113609 $\pm$ 19156	19271 $\pm$ 256

Table S3. List of genes identified as a hotspot in melanoma WES data requiring presence of the hot spot in 20 out of the 60 analyzed samples.

Ensembl gene ID	chromosome	start position	gene symbol	description	number of significant samples
ENSG00000185519	1	16057769	FAM131C	family with sequence similarity 131 member C [Source:HGNC Symbol;Acc:HGNC:26717]	27
ENSG00000142794	1	21440128	NBPF3	NBPF member 3 [Source:HGNC Symbol;Acc:HGNC:25076]	39
ENSG00000132849	1	61742477	PATJ	PATJ crumbs cell polarity complex component [Source:HGNC Symbol;Acc:HGNC:28881]	31
ENSG00000122417	1	86346824	ODF2L	outer dense fiber of sperm tails 2 like [Source:HGNC Symbol;Acc:HGNC:29225]	28
ENSG00000116299	1	109113679	ELAPOR1	endosome-lysosome associated apoptosis and autophagy regulator 1 [Source:HGNC Symbol;Acc:HGNC:29618]	26
ENSG00000237975	1	152168125	FLG-AS1	FLG antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:27913]	28
ENSG00000244414	1	196819731	CFHR1	complement factor H related 1 [Source:HGNC Symbol;Acc:HGNC:4888]	26
ENSG00000119285	1	236549005	HEATR1	HEAT repeat containing 1 [Source:HGNC Symbol;Acc:HGNC:25517]	43
ENSG00000197591	1	247840928	OR11L1	olfactory receptor family 11 subfamily L member 1 [Source:HGNC Symbol;Acc:HGNC:14998]	33
ENSG00000177462	1	247920252	OR2T8	olfactory receptor family 2 subfamily T member 8 [Source:HGNC Symbol;Acc:HGNC:15020]	37
ENSG00000224521	1	248548756	AC098483.1	novel transcript	35
ENSG00000177151	1	248636356	OR2T35	olfactory receptor family 2 subfamily T member 35 [Source:HGNC Symbol;Acc:HGNC:31257]	23
ENSG00000187701	1	248649838	OR2T27	olfactory receptor family 2 subfamily T member 27 [Source:HGNC Symbol;Acc:HGNC:31252]	32
ENSG00000134463	10	11742366	ECHDC3	enoyl-CoA hydratase domain containing 3 [Source:HGNC Symbol;Acc:HGNC:23489]	48
ENSG00000204740	10	19048801	MALRD1	MAM and LDL receptor class A domain containing 1 [Source:HGNC Symbol;Acc:HGNC:24331]	26
ENSG00000148513	10	37125725	ANKRD30A	ankyrin repeat domain 30A [Source:HGNC Symbol;Acc:HGNC:17234]	25
ENSG00000197893	10	113588714	NRAP	nebulin related anchoring protein [Source:HGNC Symbol;Acc:HGNC:7988]	42
ENSG00000288107	10	133565797	AL731769.2	novel transcript, antisense to FRG2Band SYCE1	50
ENSG00000185627	11	236966	PSMD13	proteasome 26S subunit, non-ATPase 13 [Source:HGNC Symbol;Acc:HGNC:9558]	52
ENSG00000184956	11	1012823	MUC6	mucin 6, oligomeric mucus/gel-forming [Source:HGNC Symbol;Acc:HGNC:7517]	60
ENSG00000196565	11	5253188	HGB2	hemoglobin subunit gamma 2 [Source:HGNC Symbol;Acc:HGNC:4832]	38
ENSG00000239920	11	5254392	AC104389.5	novel transcript	39
ENSG00000132256	11	5663195	TRIM5	tripartite motif containing 5 [Source:HGNC Symbol;Acc:HGNC:16276]	40
ENSG00000271758	11	7704628	AC044810.3	novel transcript, sense overlapping OR5P2, OR5P3 and OR5P1P	20
ENSG00000255071	11	18231423	SAA2-SAA4	SAA2-SAA4 readthrough [Source:HGNC Symbol;Acc:HGNC:39550]	25
ENSG00000172199	11	56375624	OR8U1	olfactory receptor family 8 subfamily U member 1 [Source:HGNC Symbol;Acc:HGNC:19611]	60
ENSG00000174914	11	56699095	OR9G1	olfactory receptor family 9 subfamily G member 1 [Source:HGNC Symbol;Acc:HGNC:15319]	60
ENSG00000197658	11	63079940	SLC22A24	solute carrier family 22 member 24 [Source:HGNC Symbol;Acc:HGNC:28542]	35
ENSG00000173153	11	64305497	ESRRA	estrogen related receptor alpha [Source:HGNC Symbol;Acc:HGNC:3471]	27
ENSG00000137675	11	102691487	MMP27	matrix metalloproteinase 27 [Source:HGNC Symbol;Acc:HGNC:14250]	23
ENSG00000182634	11	124036013	OR10G7	olfactory receptor family 10 subfamily G member 7 [Source:HGNC Symbol;Acc:HGNC:14842]	25

Gil J. et al. | Malignant melanoma proteogenomics

ENSG00000120451	11	130866250	SNX19	sorting nexin 19 [Source:HGNC Symbol;Acc:HGNC:21532]	21
ENSG00000111704	12	7787794	NANOG	Nanog homeobox [Source:HGNC Symbol;Acc:HGNC:20857]	52
ENSG00000166535	12	8822621	A2ML1	alpha-2-macroglobulin like 1 [Source:HGNC Symbol;Acc:HGNC:23336]	26
ENSG00000255641	12	10412312	AC068775.1	novel protein	58
ENSG00000231887	12	10824960	PRH1	proline rich protein HaeIII subfamily 1 [Source:HGNC Symbol;Acc:HGNC:9366]	58
ENSG00000188906	12	40196744	LRRK2	leucine rich repeat kinase 2 [Source:HGNC Symbol;Acc:HGNC:18618]	23
ENSG00000151233	12	42081845	GXYLT1	glucoside xylosyltransferase 1 [Source:HGNC Symbol;Acc:HGNC:27482]	41
ENSG00000240654	13	24307166	C1QTNF9	C1q and TNF related 9 [Source:HGNC Symbol;Acc:HGNC:28732]	29
ENSG00000102699	13	24420931	PARP4	poly(ADP-ribose) polymerase family member 4 [Source:HGNC Symbol;Acc:HGNC:271]	47
ENSG00000151846	13	25096136	PABPC3	poly(A) binding protein cytoplasmic 3 [Source:HGNC Symbol;Acc:HGNC:8556]	57
ENSG00000134871	13	110305812	COL4A2	collagen type IV alpha 2 chain [Source:HGNC Symbol;Acc:HGNC:2203]	21
ENSG00000257115	14	18601045	OR11H12	olfactory receptor family 11 subfamily H member 12 [Source:HGNC Symbol;Acc:HGNC:30738]	24
ENSG00000176219	14	20223710	OR11H6	olfactory receptor family 11 subfamily H member 6 [Source:HGNC Symbol;Acc:HGNC:15349]	28
ENSG00000181803	14	20640696	OR6S1	olfactory receptor family 6 subfamily 5 member 1 [Source:HGNC Symbol;Acc:HGNC:15363]	20
ENSG00000185567	14	104937244	AHNAK2	AHNAK nucleoprotein 2 [Source:HGNC Symbol;Acc:HGNC:20125]	44
ENSG00000174450	15	23439038	GOLGA6L2	golgin A6 family like 2 [Source:HGNC Symbol;Acc:HGNC:26695]	39
ENSG00000136378	15	78759206	ADAMTS7	ADAM metalloproteinase with thrombospondin type 1 motif 7 [Source:HGNC Symbol;Acc:HGNC:223]	45
ENSG00000196557	16	1153106	CACNA1H	calcium voltage-gated channel subunit alpha1 H [Source:HGNC Symbol;Acc:HGNC:1395]	22
ENSG00000172236	16	1240379	TPSAB1	trypsin alpha/beta 1 [Source:HGNC Symbol;Acc:HGNC:12019]	30
ENSG00000095917	16	1256059	TPSD1	trypsin delta 1 [Source:HGNC Symbol;Acc:HGNC:14118]	39
ENSG00000251692	16	1485886	PTX4	pentraxin 4 [Source:HGNC Symbol;Acc:HGNC:14171]	25
ENSG00000198848	16	55802851	CES1	carboxylesterase 1 [Source:HGNC Symbol;Acc:HGNC:1863]	26
ENSG00000125166	16	58707131	GOT2	glutamic-oxaloacetic transaminase 2 [Source:HGNC Symbol;Acc:HGNC:4433]	21
ENSG00000157322	16	69950705	CLEC18A	C-type lectin domain family 18 member A [Source:HGNC Symbol;Acc:HGNC:30388]	27
ENSG00000277481	16	71929538	PKD1L3	polycystin 1 like 3, transient receptor potential channel interacting [Source:HGNC Symbol;Acc:HGNC:21716]	24
ENSG00000034152	17	21284672	MAP2K3	mitogen-activated protein kinase kinase 3 [Source:HGNC Symbol;Acc:HGNC:6843]	60
ENSG00000184185	17	21376357	KCNJ12	potassium inwardly rectifying channel subfamily J member 12 [Source:HGNC Symbol;Acc:HGNC:6258]	60
ENSG00000204889	17	40977716	KRT40	keratin 40 [Source:HGNC Symbol;Acc:HGNC:26707]	35
ENSG00000236396	18	11609596	SLC35G4	solute carrier family 35 member G4 [Source:HGNC Symbol;Acc:HGNC:31043]	41
ENSG00000198796	18	58481247	ALPK2	alpha kinase 2 [Source:HGNC Symbol;Acc:HGNC:20565]	33
ENSG00000197563	18	61905255	PIGN	phosphatidylinositol glycan anchor biosynthesis class N [Source:HGNC Symbol;Acc:HGNC:8967]	29
ENSG00000116032	19	1000419	GRIN3B	glutamate ionotropic receptor NMDA type subunit 3B [Source:HGNC Symbol;Acc:HGNC:16768]	29
ENSG00000064666	19	1026586	CNN2	calponin 2 [Source:HGNC Symbol;Acc:HGNC:2156]	56
ENSG00000167676	19	4502180	PLIN4	perilipin 4 [Source:HGNC Symbol;Acc:HGNC:29393]	23
ENSG00000130383	19	5865826	FUT5	fucosyltransferase 5 [Source:HGNC Symbol;Acc:HGNC:4016]	24
ENSG00000181143	19	8848844	MUC16	mucin 16, cell surface associated [Source:HGNC Symbol;Acc:HGNC:15582]	55
ENSG00000198453	19	36916329	ZNF568	zinc finger protein 568 [Source:HGNC Symbol;Acc:HGNC:25392]	40
ENSG00000268797	19	40801297	AC008537.1	novel protein	28
ENSG00000198633	19	52429187	ZNF534	zinc finger protein 534 [Source:HGNC Symbol;Acc:HGNC:26337]	43
ENSG00000239998	19	54572920	LILRA2	leukocyte immunoglobulin like receptor A2 [Source:HGNC Symbol;Acc:HGNC:6603]	55
ENSG00000104974	19	54593582	LILRA1	leukocyte immunoglobulin like receptor A1 [Source:HGNC Symbol;Acc:HGNC:6602]	25
ENSG00000104972	19	54617158	LILRB1	leukocyte immunoglobulin like receptor B1 [Source:HGNC Symbol;Acc:HGNC:6605]	54
ENSG00000267265	19	55006193	AC011476.3	novel transcript, antisense to RDH13 and GP6	26
ENSG00000223638	19	55759014	RFPL4A	ret finger protein like 4A [Source:HGNC Symbol;Acc:HGNC:16449]	32
ENSG00000229292	19	55769118	RFPL4AL1	ret finger protein like 4A like 1 [Source:HGNC Symbol;Acc:HGNC:45147]	56
ENSG00000219626	2	24076526	FAM228B	family with sequence similarity 228 member B [Source:HGNC Symbol;Acc:HGNC:24736]	21
ENSG00000135976	2	97113153	ANKRD36	ankyrin repeat domain 36 [Source:HGNC Symbol;Acc:HGNC:24079]	56
ENSG00000152086	2	130191745	TUBA3E	tubulin alpha 3e [Source:HGNC Symbol;Acc:HGNC:20765]	37
ENSG00000185038	2	233775679	MROH2A	maestro heat like repeat family member 2A [Source:HGNC Symbol;Acc:HGNC:27936]	30
ENSG00000260861	20	1540144	AL049634.2	novel protein, SIRPB1-SIRPD readthrough	29
ENSG00000154719	21	25585656	MRPL39	mitochondrial ribosomal protein L39 [Source:HGNC Symbol;Acc:HGNC:14027]	27
ENSG00000175894	21	44497893	TSPEAR	thrombospondin type laminin G domain and EAR repeats [Source:HGNC Symbol;Acc:HGNC:1268]	35
ENSG00000073146	22	50089879	MOV10L1	Mov10 like RISC complex RNA helicase 1 [Source:HGNC Symbol;Acc:HGNC:7201]	20
ENSG00000144554	3	10026414	FANCD2	FA complementation group D2 [Source:HGNC Symbol;Acc:HGNC:3585]	38
ENSG00000168038	3	41246599	ULK4	unc-51 like kinase 4 [Source:HGNC Symbol;Acc:HGNC:15784]	30
ENSG00000242516	3	75672300	LINC00960	long intergenic non-protein coding RNA 960 [Source:HGNC Symbol;Acc:HGNC:48710]	56
ENSG00000172139	3	112140898	SLC9C1	solute carrier family 9 member C1 [Source:HGNC Symbol;Acc:HGNC:31401]	50
ENSG00000169064	3	167239843	ZBBX	zinc finger B-box domain containing [Source:HGNC Symbol;Acc:HGNC:26245]	32
ENSG00000177694	3	174438573	NAALADL2	N-acetylated alpha-linked acidic dipeptidase like 2 [Source:HGNC Symbol;Acc:HGNC:23219]	23
ENSG00000152492	3	191329085	CCDC50	coiled-coil domain containing 50 [Source:HGNC Symbol;Acc:HGNC:18111]	38
ENSG00000242086	3	19568062	MUC20-OT1	MUC20 overlapping transcript [Source:HGNC Symbol;Acc:HGNC:53807]	42
ENSG00000145113	3	195746765	MUC4	mucin 4, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7514]	49
ENSG00000164037	4	102885048	SLC9B1	solute carrier family 9 member B1 [Source:HGNC Symbol;Acc:HGNC:24244]	33
ENSG00000181381	4	168356735	DDX60L	DDX60/H-box 60 like [Source:HGNC Symbol;Acc:HGNC:26429]	34
ENSG00000113492	5	34998101	AGXT2	alanine-glyoxylate aminotransferase 2 [Source:HGNC Symbol;Acc:HGNC:14412]	30
ENSG00000129595	5	112142441	EPB41L4A	erythrocyte membrane protein band 4.1 like 4A [Source:HGNC Symbol;Acc:HGNC:13278]	21
ENSG00000133710	5	148025683	SPINK5	serine peptidase inhibitor Kazal type 5 [Source:HGNC Symbol;Acc:HGNC:15464]	42
ENSG00000206503	6	29941260	HLA-A	major histocompatibility complex, class I, A [Source:HGNC Symbol;Acc:HGNC:4931]	52
ENSG00000261272	6	31010474	MUC22	mucin 22 [Source:HGNC Symbol;Acc:HGNC:39755]	20
ENSG00000204536	6	31142439	CCHCR1	coiled-coil alpha-helical rod protein 1 [Source:HGNC Symbol;Acc:HGNC:13930]	33
ENSG00000204525	6	31268749	HLA-C	major histocompatibility complex, class I, C [Source:HGNC Symbol;Acc:HGNC:4933]	58
ENSG00000234745	6	31353872	HLA-B	major histocompatibility complex, class I, B [Source:HGNC Symbol;Acc:HGNC:4932]	58

Gil J. et al. | Malignant melanoma proteogenomics

ENSG00000204520	6	31399784	MICA	MHC class I polypeptide-related sequence A [Source:HGNC Symbol;Acc:HGNC:7090]	25
ENSG00000168477	6	32041153	TNXB	tenascin XB [Source:HGNC Symbol;Acc:HGNC:11976]	23
ENSG00000225914	6	32254640	TSBP1-AS1	TSBP1 and BTNL2 antisense RNA 1 [Source:HGNC Symbol;Acc:HGNC:39756]	29
ENSG00000198502	6	32517353	HLA-DRB5	major histocompatibility complex, class II, DR beta 5 [Source:HGNC Symbol;Acc:HGNC:4953]	53
ENSG00000196126	6	32578769	HLA-DRB1	major histocompatibility complex, class II, DR beta 1 [Source:HGNC Symbol;Acc:HGNC:4948]	60
ENSG00000196735	6	32628179	HLA-DQA1	major histocompatibility complex, class II, DQ alpha 1 [Source:HGNC Symbol;Acc:HGNC:4942]	53
ENSG00000179344	6	32659467	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1 [Source:HGNC Symbol;Acc:HGNC:4944]	59
ENSG00000237541	6	32741391	HLA-DQA2	major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC Symbol;Acc:HGNC:4943]	43
ENSG00000232629	6	32756098	HLA-DQB2	major histocompatibility complex, class II, DQ beta 2 [Source:HGNC Symbol;Acc:HGNC:4945]	35
ENSG00000231389	6	33064569	HLA-DPA1	major histocompatibility complex, class II, DP alpha 1 [Source:HGNC Symbol;Acc:HGNC:4938]	24
ENSG00000176381	6	166305300	PRR18	proline rich 18 [Source:HGNC Symbol;Acc:HGNC:28574]	24
ENSG00000146733	7	56011051	PSPH	phosphoserine phosphatase [Source:HGNC Symbol;Acc:HGNC:9577]	25
ENSG00000205277	7	100969623	MUC12	mucin 12, cell surface associated [Source:HGNC Symbol;Acc:HGNC:7510]	57
ENSG00000204983	7	142749468	PRSS1	serine protease 1 [Source:HGNC Symbol;Acc:HGNC:9475]	48
ENSG00000177710	8	11331012	SLC35G5	solute carrier family 35 member G5 [Source:HGNC Symbol;Acc:HGNC:15546]	20
ENSG00000145002	8	12425614	FAM86B2	family with sequence similarity 86 member B2 [Source:HGNC Symbol;Acc:HGNC:32222]	25
ENSG00000104763	8	18055992	ASAHI	N-acylsphingosine amidohydrolase 1 [Source:HGNC Symbol;Acc:HGNC:735]	20
ENSG00000253125	8	22690150	AC055854.1	novel transcript	20
ENSG00000070756	8	100685816	PABPC1	poly(A) binding protein cytoplasmic 1 [Source:HGNC Symbol;Acc:HGNC:8554]	56
ENSG00000156795	8	123416726	NTAQ1	N-terminal glutamine amidase 1 [Source:HGNC Symbol;Acc:HGNC:25490]	21
ENSG00000044459	9	17134982	CNTLN	centlein [Source:HGNC Symbol;Acc:HGNC:23432]	25
ENSG00000010438	9	33750679	PRSS3	serine protease 3 [Source:HGNC Symbol;Acc:HGNC:9486]	51
ENSG00000137054	9	37485948	POLR1E	RNA polymerase I subunit E [Source:HGNC Symbol;Acc:HGNC:17631]	23
ENSG00000106772	9	76611376	PRUNE2	prune homolog 2 with BCH domain [Source:HGNC Symbol;Acc:HGNC:25209]	25
ENSG00000277556	9	104598457	OR13C5	olfactory receptor family 13 subfamily C member 5 [Source:HGNC Symbol;Acc:HGNC:15100]	27
ENSG00000165181	9	111686173	SHOC1	shortage in chiasmata 1 [Source:HGNC Symbol;Acc:HGNC:26535]	23
ENSG00000122136	9	135546126	OBP2A	odorant binding protein 2A [Source:HGNC Symbol;Acc:HGNC:23380]	20
ENSG00000005022	NA	119468422	SLC25A5	solute carrier family 25 member 5 [Source:HGNC Symbol;Acc:HGNC:10991]	59
ENSG00000147274	NA	136848004	RBMX	RNA binding motif protein X-linked [Source:HGNC Symbol;Acc:HGNC:9910]	40

Table S4. Summary statistics showing the average number of somatic and germline mutations in 16 KEGG pathways known to be dysregulated in melanoma. The pathways were selected our proteomic data and previous knowledge.

No. of genes in the pathway	No. of genes detected in WES data	KEGGID	Pathway	Number of somatic mutations	Number of germline mutations
133	105	hsa00190	Oxidative phosphorylation	202 ± 52	17 ± 4
51	45	hsa00330	Arginine and proline metabolism	187 ± 45	21 ± 4
48	46	hsa00280	Valine, leucine and isoleucine degradation	146 ± 41	20 ± 3
57	47	hsa00480	Glutathione metabolism	153 ± 38	11 ± 3
151	123	hsa03040	Spliceosome	485 ± 117	26 ± 7
98	88	hsa03015	mRNA surveillance pathway	422 ± 98	56 ± 10
46	42	hsa03050	Proteasome	120 ± 31	12 ± 4
294	276	hsa04010	MAPK signaling pathway	1568 ± 313	118 ± 13
240	214	hsa04020	Calcium signaling pathway	1578 ± 300	179 ± 14
354	317	hsa04151	PI3K-Akt signaling pathway	1932 ± 383	222 ± 17
120	109	hsa04152	AMPK signaling pathway	634 ± 131	48 ± 7
166	158	hsa04310	Wnt signaling pathway	832 ± 170	55 ± 6
67	52	hsa00010	Glycolysis / Gluconeogenesis	218 ± 54	28 ± 5
140	131	hsa04120	Ubiquitin mediated proteolysis	701 ± 179	45 ± 6
79	75	hsa03018	RNA degradation	315 ± 79	55 ± 11
109	95	hsa04066	HIF-1 signaling pathway	494 ± 112	35 ± 6